Peringatan Keamanan

Rhabdomyolysis, liver concerns

Cerivastatin

DB00439

small molecule approved withdrawn

Deskripsi

On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.A669,L43942

Struktur Molekul 2D

Berat 459.5503
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2-3 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

The mean absolute oral bioavailability 60% (range 39 - 101%).

Metabolisme

Hepatic. Biotransformation pathways for cerivastatin in humans include the following: demethylation of the benzylic methyl ether to form Ml and hydroxylation of the methyl group in the 6'-isopropyl moiety to form M23.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid grapefruit products.
  • 2. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

987 Data
Reserpine Reserpine may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Progesterone Progesterone may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Chlorpromazine Chlorpromazine may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Cimetidine Cimetidine may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Bosentan Bosentan may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Glyburide Glyburide may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Ursodeoxycholic acid Ursodeoxycholic acid may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Cholic Acid Cholic Acid may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Simeprevir Simeprevir may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Lenvatinib Lenvatinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Letermovir The metabolism of Cerivastatin can be decreased when combined with Letermovir.
Valinomycin Valinomycin may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Olmesartan Olmesartan may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Pralsetinib Pralsetinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Erythromycin The serum concentration of Cerivastatin can be increased when it is combined with Erythromycin.
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Cerivastatin.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Cerivastatin.
Acipimox Acipimox may increase the myopathic rhabdomyolysis activities of Cerivastatin.
Bezafibrate Bezafibrate may increase the myopathic rhabdomyolysis activities of Cerivastatin.
Ciprofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Cerivastatin.
Daptomycin The risk or severity of myopathy can be increased when Cerivastatin is combined with Daptomycin.
Gemfibrozil The risk or severity of rhabdomyolysis, myoglobinuria, and elevated creatine kinase (CPK) can be increased when Gemfibrozil is combined with Cerivastatin.
Niacin The risk or severity of myopathy and rhabdomyolysis can be increased when Niacin is combined with Cerivastatin.
Pazopanib Cerivastatin may increase the hepatotoxic activities of Pazopanib.
Raltegravir The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Cerivastatin.
Trabectedin The risk or severity of myopathy and rhabdomyolysis can be increased when Cerivastatin is combined with Trabectedin.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Cerivastatin.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Cerivastatin.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Cerivastatin.
Colchicine Colchicine may increase the myopathic rhabdomyolysis activities of Cerivastatin.
Fentanyl The metabolism of Fentanyl can be decreased when combined with Cerivastatin.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Cerivastatin.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Cerivastatin.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Cerivastatin.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Cerivastatin.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Cerivastatin.
Amiodarone The metabolism of Cerivastatin can be increased when combined with Amiodarone.
Danazol The serum concentration of Cerivastatin can be increased when it is combined with Danazol.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Cerivastatin.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Cerivastatin.
Colestipol Colestipol can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevelamer Sevelamer can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colesevelam Colesevelam can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholestyramine Cholestyramine can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Cerivastatin.
Mifepristone The serum concentration of Cerivastatin can be increased when it is combined with Mifepristone.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Cerivastatin.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Cerivastatin.
Perampanel The metabolism of Perampanel can be increased when combined with Cerivastatin.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Cerivastatin.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Cerivastatin.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Cerivastatin.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Cerivastatin.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Cerivastatin.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Cerivastatin.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Cerivastatin.
Clopidogrel The serum concentration of Cerivastatin can be increased when it is combined with Clopidogrel.
Zidovudine The metabolism of Cerivastatin can be increased when combined with Zidovudine.
Lamotrigine The metabolism of Cerivastatin can be increased when combined with Lamotrigine.
Ethinylestradiol Ethinylestradiol may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Testosterone propionate The metabolism of Cerivastatin can be increased when combined with Testosterone propionate.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Cerivastatin.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Cerivastatin.
Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Cerivastatin.
Fusidic acid The risk or severity of rhabdomyolysis can be increased when Fusidic acid is combined with Cerivastatin.
Phenindione The risk or severity of bleeding can be increased when Cerivastatin is combined with Phenindione.
Tioclomarol The risk or severity of bleeding can be increased when Cerivastatin is combined with Tioclomarol.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Cerivastatin is combined with Ethyl biscoumacetate.
Diphenadione The risk or severity of bleeding can be increased when Cerivastatin is combined with Diphenadione.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Cerivastatin is combined with 4-hydroxycoumarin.
Clorindione The risk or severity of bleeding can be increased when Cerivastatin is combined with Clorindione.
Clofibrate The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Cerivastatin.
Fenofibrate The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Cerivastatin.
Etofibrate The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Cerivastatin.
Simfibrate The risk or severity of myopathy and rhabdomyolysis can be increased when Simfibrate is combined with Cerivastatin.
Ronifibrate The risk or severity of myopathy and rhabdomyolysis can be increased when Ronifibrate is combined with Cerivastatin.
Aluminium clofibrate The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Cerivastatin.
Clofibride The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibride is combined with Cerivastatin.
Fenofibric acid The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibric acid is combined with Cerivastatin.
Secobarbital The metabolism of Cerivastatin can be increased when combined with Secobarbital.
Bexarotene The metabolism of Cerivastatin can be decreased when combined with Bexarotene.
Nabilone The metabolism of Nabilone can be decreased when combined with Cerivastatin.
Medroxyprogesterone acetate The metabolism of Cerivastatin can be decreased when combined with Medroxyprogesterone acetate.
Nicardipine The metabolism of Cerivastatin can be decreased when combined with Nicardipine.
Irbesartan The metabolism of Cerivastatin can be decreased when combined with Irbesartan.
Oxybutynin The metabolism of Cerivastatin can be decreased when combined with Oxybutynin.
Fluvastatin The metabolism of Cerivastatin can be decreased when combined with Fluvastatin.
Pioglitazone The metabolism of Cerivastatin can be decreased when combined with Pioglitazone.
Loratadine The metabolism of Cerivastatin can be decreased when combined with Loratadine.
Levothyroxine The metabolism of Cerivastatin can be decreased when combined with Levothyroxine.
Abiraterone The metabolism of Cerivastatin can be decreased when combined with Abiraterone.
Fluticasone propionate The metabolism of Cerivastatin can be decreased when combined with Fluticasone propionate.
Candesartan cilexetil The metabolism of Cerivastatin can be decreased when combined with Candesartan cilexetil.
Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Cerivastatin.
Fluticasone The metabolism of Cerivastatin can be decreased when combined with Fluticasone.
Mometasone furoate The metabolism of Cerivastatin can be decreased when combined with Mometasone furoate.
Salmeterol The metabolism of Cerivastatin can be decreased when combined with Salmeterol.
Felodipine The metabolism of Cerivastatin can be decreased when combined with Felodipine.
Lanthanum carbonate The absorption of Cerivastatin can be decreased when combined with Lanthanum carbonate.
Clarithromycin The metabolism of Cerivastatin can be decreased when combined with Clarithromycin.

Target Protein

3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 11806796
    Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2(5):205-207.

Contoh Produk & Brand

Produk: 4 • International brands: 2
Produk
  • Baycol
    Tablet • 0.4 mg / tab • Oral • Canada • Approved
  • Baycol
    Tablet • 0.8 mg • Oral • Canada • Approved
  • Baycol (0.2mg)
    Tablet • 0.2 mg / tab • Oral • Canada • Approved
  • Baycol (0.3mg)
    Tablet • 0.3 mg / tab • Oral • Canada • Approved
International Brands
  • Lipobay
  • Rivastatin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul